UCB S.A.
UCB
주식 순위
#526
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
주가
$240.91
시가총액
$45.93B
변동 (1일)
-0.73%
변동 (1년)
-16.89%
국가
BE
거래 UCB S.A. (UCB)
카테고리
Healthcare
UCB S.A. (UCB)의 배당 이력
UCB S.A. (주식 심볼: UCB)은 총 29회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): $27.69
배당 수익률 (TTM): 0.0072
모든 배당금의 합계 (주식 분할 반영): $27.69
배당 수익률 (TTM): 0.0072
UCB S.A. (UCB)의 2000부터 2026까지 배당 지급 내역
연간 배당 지급
| 연도 | 배당금 (주식 분할 조정됨) | 변화 |
|---|---|---|
| 2026 (TTM) | $1.20 | 0.00% |
| 2025 | $1.20 | -11.98% |
| 2024 | $1.36 | 2.26% |
| 2023 | $1.33 | 2.31% |
| 2022 | $1.30 | 2.36% |
| 2021 | $1.27 | 2.42% |
| 2020 | $1.24 | 2.48% |
| 2019 | $1.21 | 2.54% |
| 2018 | $1.18 | 2.61% |
| 2017 | $1.15 | 4.55% |
| 2016 | $1.10 | 3.77% |
| 2015 | $1.06 | 1.92% |
| 2014 | $1.04 | 1.96% |
| 2013 | $1.02 | 2.00% |
| 2012 | $1.00 | 2.04% |
| 2011 | $0.98 | 2.08% |
| 2010 | $0.96 | 4.35% |
| 2009 | $0.92 | 0.00% |
| 2008 | $0.92 | 2.22% |
| 2007 | $0.9 | 2.27% |
| 2006 | $0.88 | 2.33% |
| 2005 | $0.86 | -34.85% |
| 2004 | $1.32 | 9.09% |
| 2003 | $1.21 | 6.14% |
| 2002 | $1.14 | 78.13% |
| 2001 | $0.64 | 28.00% |
| 2000 | $0.5 | 0.00% |
모든 배당 지급 목록
| 연도 | 배당금 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.20 | 0.00% |
| 2025 | $1.20 | -11.98% |
| 2024 | $1.36 | 2.26% |
| 2023 | $1.33 | 2.31% |
| 2022 | $1.30 | 2.36% |
| 2021 | $1.27 | 2.42% |
| 2020 | $1.24 | 2.48% |
| 2019 | $1.21 | 2.54% |
| 2018 | $1.18 | 2.61% |
| 2017 | $1.15 | 4.55% |
| 2016 | $1.10 | 3.77% |
| 2015 | $1.06 | 1.92% |
| 2014 | $1.04 | 1.96% |
| 2013 | $1.02 | 2.00% |
| 2012 | $1.00 | 2.04% |
| 2011 | $0.98 | 2.08% |
| 2010 | $0.96 | 4.35% |
| 2009 | $0.92 | 0.00% |
| 2008 | $0.92 | 2.22% |
| 2007 | $0.9 | 2.27% |
| 2006 | $0.88 | 2.33% |
| 2005 | $0.86 | -34.85% |
| 2004 | $1.32 | 9.09% |
| 2003 | $1.21 | 6.14% |
| 2002 | $1.14 | 78.13% |
| 2001 | $0.64 | 28.00% |
| 2000 | $0.5 | 0.00% |
유사 기업 또는 경쟁사의 배당 지급
| 회사 | 배당 지급 횟수 | 국가 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
